Evidence map›Paper›PMID 34106957›Full record

ArticlePloS one2021

SARS-CoV-2 Envelope (E) protein interacts with PDZ-domain-2 of host tight junction protein ZO1.

Ariel Shepley-McTaggart, Cari A Sagum, Isabela Oliva, Elizabeth Rybakovsky, Katie DiGuilio, Jingjing Liang, Mark T Bedford, Joel Cassel, Marius Sudol, James M Mullin and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. SARS-CoV-2-International journal of microbiology · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. SARS-CoV-2 Is an Electricity-Driven Virus.Reviews of physiology, biochemistry and pharmacology · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Ariel Shepley-McTaggartDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Cari A SagumDepartment of Epigenetics & Molecular Carcinogenesis, M.D. Anderson Cancer Center, University of Texas, Smithville, Texas, United States of America.
Isabela OlivaThe Wistar Cancer Center for Molecular Screening, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Elizabeth RybakovskyLankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States of America.
Katie DiGuilioLankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States of America.
Jingjing LiangDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Mark T BedfordDepartment of Epigenetics & Molecular Carcinogenesis, M.D. Anderson Cancer Center, University of Texas, Smithville, Texas, United States of America.
Joel CasselThe Wistar Cancer Center for Molecular Screening, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.
Marius SudolDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
James M MullinLankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States of America.
Ronald N HartyDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-6596-0414
Lankenau Institute for Medical Research · USUniversity of Pennsylvania · USThe University of Texas MD Anderson Cancer Center · USThe Wistar Institute · USIcahn School of Medicine at Mount Sinai · US

Funding

VMD-PhD Training in Infectious Disease-Related ResearchT32AI070077 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michael Lee Atchison · 2008 to 2026
$3.5M
Dueling PPxY Motifs of Filovirus VP40 and Host Angiomotin: Effects on Innate Immune Defenses and Tight Junction Integrity at Immune Privileged SitesR21AI139392 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HARTY, RONALD N · 2018 to 2019
$462k
Modular Domains of Host Proteins Regulate Filovirus MaturationR21AI138052 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HARTY, RONALD N · 2018 to 2019
$448k
NIAID NIH HHS R21 AI138052NIAID NIH HHS R21 AI139392NIAID NIH HHS T32 AI070077NIH HHS AI138052NIH HHS AI139392
6 · The paper itself

Abstract

Newly emerged SARS-CoV-2 is the cause of an ongoing global pandemic leading to severe respiratory disease in humans. SARS-CoV-2 targets epithelial cells in the respiratory tract and lungs, which can lead to amplified chloride secretion and increased leak across epithelial barriers, contributing to severe pneumonia and consolidation of the lungs as seen in many COVID-19 patients. There is an urgent need for a better understanding of the molecular aspects that contribute to SARS-CoV-2-induced pathogenesis and for the development of approaches to mitigate these damaging pathologies. The multifunctional SARS-CoV-2 Envelope (E) protein contributes to virus assembly/egress, and as a membrane protein, also possesses viroporin channel properties that may contribute to epithelial barrier damage, pathogenesis, and disease severity. The extreme C-terminal (ECT) sequence of E also contains a putative PDZ-domain binding motif (PBM), similar to that identified in the E protein of SARS-CoV-1. Here, we screened an array of GST-PDZ domain fusion proteins using either a biotin-labeled WT or mutant ECT peptide from the SARS-CoV-2 E protein. Notably, we identified a singular specific interaction between the WT E peptide and the second PDZ domain of human Zona Occludens-1 (ZO1), one of the key regulators of TJ formation/integrity in all epithelial tissues. We used homogenous time resolve fluorescence (HTRF) as a second complementary approach to further validate this novel modular E-ZO1 interaction. We postulate that SARS-CoV-2 E interacts with ZO1 in infected epithelial cells, and this interaction may contribute, in part, to tight junction damage and epithelial barrier compromise in these cell layers leading to enhanced virus spread and severe dysfunction that leads to morbidity. Prophylactic/therapeutic intervention targeting this virus-host interaction may effectively reduce airway and/or gastrointestinal barrier damage and mitigate virus spread.

Indexed as

Coronavirus Envelope ProteinsCOVID-19Host-Pathogen InteractionsHumansPDZ DomainsProtein BindingRecombinant ProteinsSARS-CoV-2Tight JunctionsZonula Occludens-1 ProteinCoronavirus Envelope Proteinsenvelope protein, SARS-CoV-2Recombinant ProteinsTJP1 protein, humanZonula Occludens-1 Protein

Identifiers

PMID34106957
PMCPMC8189464
OpenAlexW3168171782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.